Crystal Palace have begun an investigation into allegations that midfielder Daichi Kamada was racially abused by supporters at Selhurst Park. The incident is alleged to have taken place after ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Daichi Fujioka received his Ph.D. in Mechanical Engineering from Georgia Institute of Technology in 2017. His dissertation was on an input-shaped model reference control for machines with flexible ...

Dai-Ichi Karkare Limited (DIKL) was set up in 1960 as a private limited company for the manufacture of speciality chemicals. The Company entered into technical collaboration with the ...

Back in 2011, the world held its breath after the Fukushima Daiichi nuclear plant in Japan suffered a failure of its cooling ...

(RTTNews) - Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the deal, Daiichi Sankyo will acquire world-wide rights ...

Dai-ichi Life Insurance Co. announced on Oct. 29 it will lower the estimated rate of return for the defined benefit corporate pension insurance policies it has contracted with about 3,000 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...